Félix Guerrero-Ramos, MD, PhD, FEBU, discusses key findings from the phase 3 POTOMAC trial and other studies of BCG/ICI combinations in high-risk NMIBC.
Evolving treatment paradigms in high-risk NMIBC
Bradley McGregor, MD, contextualizes recent data on emerging treatment regimens in high-risk, BCG-naïve NMIBC.
Advertisement
Advertisement
Trending on Urology Times
1
Study progresses of nogapendekin alfa inbakicept for BCG-naïve NMIBC
2
Practical uses of AI across the urologic care continuum
3
CREST and POTOMAC: Redefining immunotherapy’s role in NMIBC
4
Iman Sadri, MD, discusses novel nerve grafting strategy for erectile dysfunction after prostatectomy
5